Kerrebijn K F, van Essen-Zandvliet E E, Neijens H J
J Allergy Clin Immunol. 1987 Apr;79(4):653-9. doi: 10.1016/s0091-6749(87)80163-x.
Airway inflammation is assumed to be an important determinant in increased bronchial responsiveness (BR). We tested the hypothesis that treatment with an inhaled anti-inflammatory drug (i.e., budesonide) but not with an inhaled beta-agonist (i.e., terbutaline) would reduce BR in children with asthma and with minimal or no bronchoconstriction. Twelve patients were treated with budesonide and seven with terbutaline for 6 months. BR decreased in 11 patients receiving budesonide and was significant in seven patients. BR decreased in none of the patients receiving terbutaline. FEV1 demonstrated a small increase with budesonide but remained unchanged with terbutaline. Except in one patient who received terbutaline, the clinical effect was good. We conclude that inhaled corticosteroids but not inhaled beta-agonists will decrease persistent BR in most children with asthma.
气道炎症被认为是支气管反应性（BR）增加的一个重要决定因素。我们检验了这样一个假设：对于哮喘且支气管收缩轻微或无收缩的儿童，吸入抗炎药物（即布地奈德）而非吸入β受体激动剂（即特布他林）治疗可降低BR。12例患者接受布地奈德治疗，7例患者接受特布他林治疗，为期6个月。接受布地奈德治疗的11例患者BR降低，其中7例显著降低。接受特布他林治疗的患者中BR均未降低。使用布地奈德后第一秒用力呼气容积（FEV1）有小幅增加，但使用特布他林后FEV1保持不变。除1例接受特布他林治疗的患者外，临床效果良好。我们得出结论，对于大多数哮喘儿童，吸入糖皮质激素而非吸入β受体激动剂可降低持续性BR。
